Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

A 34-year-old woman comes to the outpatient clinic reporting a three-day history of swelling, erythema, and a dull ache in her left calf. Her past medical history is notable for systemic lupus erythematosus, currently managed with hydroxychloroquine, and a history of two unprovoked deep vein thromboses in her early twenties. She also reports a history of three consecutive first-trimester pregnancy losses.

Vital signs are:
Temperature: 37.1°C (98.8°F)
Blood pressure: 118/76 mmHg
Heart rate: 82/min
Respiratory rate: 14/min
Oxygen saturation: 99% on room air.

Physical examination reveals non-pitting edema of the left lower extremity to the level of the knee, with mild tenderness to palpation over the popliteal fossa. The right leg is normal.

A comprehensive metabolic panel and complete blood count are within normal limits.

Coagulation studies show:
Prothrombin time (PT): 13 seconds (normal: 11-15 seconds)
Partial thromboplastin time (PTT): 58 seconds (normal: 25-40 seconds)

A mixing study with normal plasma fails to correct the prolonged PTT. Compression ultrasonography of the left lower extremity demonstrates a noncompressible segment in the left popliteal vein.

Which of the following is the most appropriate pharmacologic management for this patient?

  1. Initiation of low-molecular-weight heparin and oral warfarinCevap
  2. B
    Initiation of oral apixaban
  3. C
    Initiation of oral aspirin and clopidogrel
  4. D
    Administration of intravenous alteplase
  5. E
    Deferment of pharmacologic therapy pending magnetic resonance venography

Cevap

Initiation of low-molecular-weight heparin and oral warfarin
The correct intervention involves bridging a parenteral anticoagulant (low-molecular-weight heparin) to oral warfarin. This patient's presentation—recurrent deep vein thromboses, multiple pregnancy losses, systemic lupus erythematosus, and a prolonged PTT that does not correct on a mixing study (lupus anticoagulant)—is highly diagnostic for antiphospholipid syndrome (APS). For secondary prevention of venous thromboembolism in APS, lifelong anticoagulation with a vitamin K antagonist (warfarin) is the standard of care. Because warfarin initially causes a transient procoagulant state by depleting proteins C and S, bridging with a parenteral anticoagulant is mandatory until the INR is therapeutic.

Adım Adım Çözüm

1
Analyze the patient's history and clinical presentation.
The patient has a confirmed acute deep vein thrombosis (DVT) in the setting of systemic lupus erythematosus, recurrent prior DVTs, and multiple first-trimester pregnancy losses.
Establishing the clinical phenotype is essential for recognizing underlying hypercoagulable states.
2
Interpret the laboratory findings.
A prolonged PTT that fails to correct with a mixing study indicates the presence of an inhibitor, specifically a lupus anticoagulant, confirming the diagnosis of antiphospholipid syndrome (APS).
Mixing studies differentiate between factor deficiencies (which correct) and inhibitors (which do not correct).
3
Select the appropriate pharmacologic intervention.
Warfarin, bridged with low-molecular-weight heparin, is selected over direct oral anticoagulants.
Direct oral anticoagulants have been shown to have higher rates of recurrent thrombosis in patients with APS and are currently contraindicated in this population.

Anahtar Kavram

Patients with antiphospholipid syndrome who experience a thromboembolic event require long-term anticoagulation with warfarin; direct oral anticoagulants (DOACs) are contraindicated due to a higher risk of recurrent thrombosis.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru